Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cord blood transfusions could be safer for preemies

NCT ID NCT07502781

First seen Apr 02, 2026 · Last updated Jun 23, 2026 · Updated 12 times

Summary

This study compares transfusions using umbilical cord blood versus standard adult donor blood in extremely premature infants. About 176 babies born before 28 weeks will be randomly assigned to receive either type of blood if needed. The goal is to see if cord blood reduces the risk of serious complications like lung disease, eye problems, or death.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTREMELY PREMATURE INFANT are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hospital Clínic de Barcelona - Maternitat

    Barcelona, 08028, Spain

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

umbilical cord blood red blood cells

What this could lead to

If it works, this could provide a safer and more effective transfusion option for extremely premature infants, reducing complications like lung and eye problems.

What could go wrong

This is a small pilot study, so results may not be conclusive. Cord blood may not always be available, and the benefits over standard blood are not yet proven.

Conditions

The condition(s) this trial relates to.

beta thalassemia bronchopulmonary dysplasia neonatal anemia Perinatal Death retinopathy of prematurity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.